AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+36.42%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$615M
AUM Growth
+$615M
(+23%)
Cap. Flow
+$3.99M
Cap. Flow
% of AUM
0.65%
Top 10 Holdings %
Top 10 Hldgs %
41%
Holding
112
New
24
Increased
26
Reduced
15
Closed
21
Top Buys
| 1 |
Vera Therapeutics
VERA
|
$20.3M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$16.2M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$12.8M |
| 4 |
AUTL
Autolus Therapeutics
AUTL
|
$11.6M |
| 5 |
Kura Oncology
KURA
|
$11.5M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$41.6M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$25.8M |
| 3 |
Viking Therapeutics
VKTX
|
$20.5M |
| 4 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$19M |
| 5 |
LIAN
LianBio American Depositary Shares
LIAN
|
$16.9M |
Sector Composition
| 1 | Healthcare | 92.6% |
| 2 | Financials | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Geron
GERN
$893M
| $8.25M | 1.02% |
+2,500,000
| New | +$8.25M |
|
|
MORF
27
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $7.92M | 0.98% |
225,000
+182,330
| +427% | +$6.42M |
|
28
NewAmsterdam Pharma
NAMS
$2.8B
| $6.77M | 0.84% |
286,200
+161,200
| +129% | +$3.81M |
|
|
ELEV
29
DELISTED
Elevation Oncology
ELEV
| $6.51M | 0.81% |
+1,268,825
| New | +$6.51M |
|
30
Perspective Therapeutics
CATX
$251M
| $6.07M | 0.75% |
+510,000
| New | +$6.07M |
|
31
Absci
ABSI
$356M
| $5.82M | 0.72% |
+1,025,000
| New | +$5.82M |
|
32
Savara
SVRA
$591M
| $5.73M | 0.71% |
1,150,000
| – | – |
|
33
Cytokinetics
CYTK
$5.98B
| $5.61M | 0.69% |
80,000
-80,000
| -50% | -$5.61M |
|
34
Vaxcyte
PCVX
$4.17B
| $5.46M | 0.68% |
80,000
+55,000
| +220% | +$3.76M |
|
35
Roivant Sciences
ROIV
$8.6B
| $5.27M | 0.65% |
500,000
| – | – |
|
36
Fulcrum Therapeutics
FULC
$353M
| $5.2M | 0.64% |
550,339
+425,339
| +340% | +$4.02M |
|
|
SWTX
37
DELISTED
SpringWorks Therapeutics
SWTX
| $4.92M | 0.61% |
100,000
| – | – |
|
38
Krystal Biotech
KRYS
$4.35B
| $4.76M | 0.59% |
26,746
+1,746
| +7% | +$311K |
|
39
Mersana Therapeutics
MRSN
$34.8M
| $4.48M | 0.55% |
40,000
| – | – |
|
40
Cullinan Oncology
CGEM
$456M
| $4.41M | 0.55% |
258,588
-41,412
| -14% | -$706K |
|
41
Mineralys Therapeutics
MLYS
$1.94B
| $4.23M | 0.52% |
+327,959
| New | +$4.23M |
|
|
42
Viking Therapeutics
VKTX
$3.02B
| $4.1M | 0.51% |
50,000
-250,000
| -83% | -$20.5M |
|
43
Rezolute
RZLT
$630M
| $4.08M | 0.51% |
+1,600,000
| New | +$4.08M |
|
44
Mirum Pharmaceuticals
MIRM
$3.75B
| $4.02M | 0.5% |
160,000
+110,000
| +220% | +$2.76M |
|
45
MoonLake Immunotherapeutics
MLTX
$3.78B
| $3.77M | 0.47% |
75,000
+4,012
| +6% | +$202K |
|
46
Immatics
IMTX
$662M
| $3.68M | 0.46% |
350,000
+150,000
| +75% | +$1.58M |
|
|
ITCI
47
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.46M | 0.43% |
+50,000
| New | +$3.46M |
|
48
Arrowhead Research
ARWR
$3.84B
| $3.43M | 0.42% |
+120,000
| New | +$3.43M |
|
49
NextCure
NXTC
$13.3M
| $3.03M | 0.38% |
+113,253
| New | +$3.03M |
|
50
Terns Pharmaceuticals
TERN
$651M
| $2.95M | 0.37% |
450,000
+384,000
| +582% | +$2.52M |
|